Development Group
News
The survey results are in – worst-case conditions for viral clearance
Viral clearance studies are mandated as part of the viral safety evaluation of products derived from human or other mamm...
Accelerating industry progress with the new BioPhorum Council
Accelerating industry progress with the new BioPhorum Council
BioPhorum is built on a foundation of providing value to ...
How to predict, optimize and analyze high-concentration biologic therapeutic formulations
Developing high-dose biologic drugs for subcutaneous injection often requires high-concentration formulations. It also n...
Everything you need to know about ‘ready to use’ cells … on a poster
Biologics potency is an important component of an overall CMC analytical control strategy, which is widely determined by...
BioPhorum’s Deliverables Report 2022 – all our content at your fingertips
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, posit...
How to maximize business value from process analytical technologies
Applying process analytical technologies (PAT) for biotherapeutic development and manufacturing is possible because of t...
How to make in-use stability and compatibility studies a success
In-use stability and compatibility studies are often used in biotherapeutic development to assess biologic drugs with di...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
Formulation team sweeps away barriers to sharing
Biopharmaceutical formulations often present as complex mixtures that can be sensitive to heat, light, and many other fa...
Speed to Clinic initiative launches: learning from the COVID-19 pandemic
LONG READSpeed to Clinic initiative launches: learning from the COVID-19 pandemic Spurred on by lessons learned from...
How to create a toolbox to assess your high-risk HCPs
Host cell proteins (HCPs) are process-related impurities derived from host cells that may co-purify with a biopharmaceut...
BioPhorum launch new sustainability phorum
BioPhorum members have given us a clear message; to be an industry that supports sustainability is extremely important t...
The survey results are in – worst-case conditions for viral clearance
Viral clearance studies are mandated as part of the viral safety evaluation of products derived from human or other mammalian cell lines. When acceptable ranges of process parameters are known, the ICH and EMA recommend that scale-down models are evaluated under worst-case conditions for viral clear...
Accelerating industry progress with the new BioPhorum Council
Accelerating industry progress with the new BioPhorum Council
BioPhorum is built on a foundation of providing value to ...
How to predict, optimize and analyze high-concentration biologic therapeutic formulations
Developing high-dose biologic drugs for subcutaneous injection often requires high-concentration formulations. It also n...
Everything you need to know about ‘ready to use’ cells … on a poster
Biologics potency is an important component of an overall CMC analytical control strategy, which is widely determined by...
BioPhorum’s Deliverables Report 2022 – all our content at your fingertips
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, posit...
How to maximize business value from process analytical technologies
Applying process analytical technologies (PAT) for biotherapeutic development and manufacturing is possible because of t...
How to make in-use stability and compatibility studies a success
In-use stability and compatibility studies are often used in biotherapeutic development to assess biologic drugs with di...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
Formulation team sweeps away barriers to sharing
Biopharmaceutical formulations often present as complex mixtures that can be sensitive to heat, light, and many other fa...
Speed to Clinic initiative launches: learning from the COVID-19 pandemic
LONG READSpeed to Clinic initiative launches: learning from the COVID-19 pandemic Spurred on by lessons learned from...
How to create a toolbox to assess your high-risk HCPs
Host cell proteins (HCPs) are process-related impurities derived from host cells that may co-purify with a biopharmaceut...
BioPhorum launch new sustainability phorum
BioPhorum members have given us a clear message; to be an industry that supports sustainability is extremely important t...
Chain reaction: how the biopharmaceutical supply chain survived the pandemic
LONG READChain reaction: how the biopharmaceutical supply chain survived the pandemicThe pressure on the...